Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Nestle SA | 161 |
| 2 | Idemitsu Kosan Co Ltd | 82 |
| 3 | Zevra Therapeutics Inc | 57 |
| 4 | Dow Inc | 54 |
| 5 | Innophos Inc | 22 |
| 6 | 3M Co | 21 |
| 7 | BASF SE | 21 |
| 8 | Centre National de la Recherche Scientifique | 20 |
| 9 | Indian Oil Corp Ltd | 20 |
| 10 | Sakata Inx Corp | 19 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 768 |
| 2 | A61P | Therapeutic activity (drug indications) | 665 |
| 3 | C08G | Polymers from non-vinyl bonds (e.g. polyamides, polyesters) | 365 |
| 4 | C08L | Polymer compositions (blends) | 274 |
| 5 | C07D | Heterocyclic compounds | 219 |
| 6 | A23L | Foods and beverages (general) | 212 |
| 7 | C09D | Coatings, paints, varnishes | 189 |
| 8 | C07C | Acyclic and carbocyclic compounds | 165 |
| 9 | A23V | Foods, foodstuffs - indexing scheme | 139 |
| 10 | C08K | Polymer compositions (additives) | 139 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| MASKED CYTOKINE POLYPEPTIDES | 2020 | Xilio Therapeutics Inc | 68 |
| SPECIFIC BACTERIAL SPECIES AND METABOLITE THAT IMPROVES IMMUNE CHECKPOINT INHIBITOR THERAPY EFFICACY | 2018 | The University of Texas System | 53 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | 2008 | Excrx Singapore Pte Ltd | 112 |
| Pentanediisocyanate, process for producing pentamethylenediisocyanate, polyisocyanate composition, polyurethane resin, and polyurea resin | 2013 | Mitsui Chemicals Inc | 79 |
| MASKED IL-12 CYTOKINES AND THEIR CLEAVAGE PRODUCTS | 2021 | 24 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Isao Kubo | University of California, Berkeley | 7 |
| 2 | Antonello Mai | Sapienza University of Rome | 5 |
| 3 | Lucia Altucci | University of Naples Federico II | 5 |
| 4 | Gianluca Sbardella | University of Salerno | 4 |
| 5 | R. Paramashivappa | Vittal Mallya Scientific Research Foundation | 4 |
| 6 | Frank J. Dekker | University of Groningen | 3 |
| 7 | Hidde J. Haisma | University of Groningen | 3 |
| 8 | Angela Nebbioso | University of Naples Federico II | 3 |
| 9 | Sabrina Castellano | University of Salerno | 3 |
| 10 | P. Sriramarao | Vittal Mallya Scientific Research Foundation | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells | 2012 | 563 | Pluripotent Stem Cells Research |
| Small Molecule Modulators of Histone Acetyltransferase p300 | 2003 | 517 | Ubiquitin and proteasome pathways |
| Characterization of alkyl phenols in cashew (Anacardium occidentale) products and assay of their antioxidant capacity | 2005 | 365 | Phytochemicals and Antioxidant Activities |
| Ginkgolic Acid Inhibits Protein SUMOylation by Blocking Formation of the E1-SUMO Intermediate | 2009 | 350 | Cancer-related Molecular Pathways |
| Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-κB–regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-κBα kinase, leading to potentiation of apoptosis | 2008 | 263 | Ginkgo biloba and Cashew Applications |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of 2-hydroxy-6-pentadeca-8,11,14-trienylbenzoic acid?
Which organizations hold the most patents related to this compound?
What has been the trend in patent filings for this compound in recent years?
Which academic researchers have published the most papers on this compound?
What are the primary patent technology classifications for this compound?